老年淋巴瘤患者应用PEG-rhG-CSF进行初级预防的疗效分析

施晴; 王黎; 张慕晨; 闫子勋; 许彭鹏; 赵维莅; 钱樱

doi:10.13201/j.issn.1004-2806.2018.11.006

老年淋巴瘤患者应用PEG-rhG-CSF进行初级预防的疗效分析

- 医学基因组学国家重点实验室, 上海血液学研究所, 上海交通大学医学院附属瑞金医院(上海, 200025)△. 共同第一作者
基金项目:
国家自然科学基金(No:81830007,81520108003,81670716)

上海市科委课题(No:14430723400,14140903100,16JC1405800)

上海市杰出青年医学人才培养计划

上海市教委高原高峰计划(No:20152206,20152208)

详细信息

通讯作者: 钱樱,E-mail:ljj10395502@163.com

中图分类号: R733.4

收稿日期: 2018-07-25

Efficacy analysis of PEG-rhG-CSF as primary prophylaxis in senile lymphoma patients

- Department of Hematology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China

More Information

Corresponding author: QIAN Ying, E-mail: ljj10395502@163.com

Received Date: 25 July 2018

摘要

摘要: 目的:评价聚乙二醇化重组人粒细胞集落刺激因子(PEG-rhG-CSF)应用于预防老年淋巴瘤患者化疗后引起中性粒细胞缺乏(粒缺)的有效性和安全性。方法:回顾性分析84例老年(≥ 60岁)淋巴瘤化疗患者的病例资料。根据个人意愿,36例患者接受PEG-rhG-CSF作为初级预防(试验组);48例未预防性使用PEG-rhG-CSF(对照组),比较2组患者出现3~4级粒缺的情况及药物所致不良反应。结果:试验组和对照组中分别有61.1%和87.5%的患者在全部化疗周期中出现过3~4级粒缺,差异有统计学意义(P=0.005)。亚组分析显示,60~69岁患者中,试验组3~4级粒缺的发生率显著低于对照组(62.1%:86.5%,P=0.022);70岁及以上患者中,试验组3~4级粒缺的发生率有降低趋势,但与对照组比较差异无统计学意义(57.1%:90.9%,P=0.137)。在接受PEG-rhG-CSF预防性应用的36例患者中,有8例(22.2%)出现药物相关性不良反应,主要表现为轻微骨痛。结论:对于接受21 d CHOP±R化疗方案的老年淋巴瘤患者,每疗程一剂6 mg PEG-rhG-CSF能有效减少3~4级粒缺的发生,疗效显著,且不良反应发生率低,程度轻。
- 老年 /
- 聚乙二醇化重组人粒细胞集落刺激因子 /
- 淋巴瘤 /
- 化疗 /
- 中性粒细胞减少
Abstract: Objective:To evaluate the safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) as primary prophylaxis for chemotherapy-induced neutropenia in senile lymphoma patients.Method:A total of 84 elder lymphoma patients (≥ 60 years old) treated with chemotherapy were included.Among them,36 patients receiving PEG-rhG-CSF as primary prevention were considered as the prevention group;48 patients without PEG-rhG-CSF injection were recruited as the control group.The incidence of grade 3-4 neutropenia of two groups and the adverse events induced by PEG-rhG-CSF were recorded and compared.Result:61.1% patients in prevention group and 87.5% patients in control group had experienced grade 3-4 neutropenia respectively.There was significant difference between the two groups (P=0.005).Subgroup analysis showed significant lower incidence of grade 3-4 neutropenia in the prevention group (62.1% vs 86.5%,P=0.022) for patients of 60-69 years old.For patients aged 70 and over,lower incidence of grade 3-4 neutropenia was also observed in the prevention group,but the difference was not statistically significant (57.1% vs 90.9%,P=0.137).As for adverse events of PEG-rhG-CSF,8 cases in 36 patients (22.2%) experienced slight bone pain.Conclusion:In senile lymphoma patients undergoing 21 d-CHOP±R regimen,a single dose of 6 mg PEG-rhG-CSF demonstrated significant prophylaxis for grade 3-4 neutropenia,with low incidence of adverse events and mild adverse events.
- senile /
- pegylated recombinant human granulocyte colony-stimulating factor /
- lymphoma /
- chemo therapy /
- neutropenia

HTML全文

参考文献(24)

[1]	Cunningham D,Hawkes EA,Jack A,et al.Rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma:a phase 3 comparison of dose intensification with 14-day versus 21-day cycles[J].Lancet,2013,381:1817-1826.
[2]	Delarue R,Tilly H,Mounier N,et al.Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study):a randomised phase 3 trial[J].Lancet Oncol,2013,14:525-533.
[3]	Epelbaum R,Faraggi D,Ben-Arie Y,et al.Survival of diffuse large cell lymphoma.A multivariate analysis including dose intensity variables[J].Cancer,1990,66:1124-1129.
[4]	Terada Y,Nakamae H,Aimoto R,et al.Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma[J].J Exp Clin Cancer Res,2009,28:116.
[5]	Gutierrez A,Bento L,Bautista-Gili AM,et al.Differential impact of relative dose-intensity reductions in diffuse large B-cell lymphoma treated with R-CHOP21 or R-CHOP14[J].PLoS One,2015,10:e123978.
[6]	Kaushansky K.Lineage-specific hematopoietic growth factors[J].N Engl J Med,2006,354:2034-2045.
[7]	Lyman GH,Dale DC,Culakova E,et al.The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival:a systematic review and meta-analysis of randomized controlled trials[J].Ann Oncol,2013,24:2475-2484.
[8]	Kubo K,Miyazaki Y,Murayama T,et al.A randomized,double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE (R) chemotherapy for malignant lymphoma[J].Br J Haematol,2016,174:563-570.
[9]	Balducci L,Mo M,Abella E,et al.Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim[J].Am J Clin Oncol,2014,37:603-610.
[10]	Cerchione C,De Renzo A,Di Perna M,et al.Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma:a single center,real-life experience[J].Support Care Cancer,2017,25:839-845.
[11]	Lathia N,Isogai PK,De Angelis C,et al.Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients[J].J Natl Cancer Inst,2013,105:1078-1085.
[12]	马军,朱军,徐兵河,等.聚乙二醇化重组人粒细胞刺激因子(PEG-rhG-CSF)临床应用中国专家共识[J].中国肿瘤临床,2016,43(7):271-274.
[13]	金静霞,郑翠苹,陈丽雅,等.PD-1、PD-L1在弥漫大B细胞淋巴瘤组织中的差异性表达及其临床意义[J].临床血液学杂志,2018,31(1):34-37.
[14]	朱明霞,万文丽,洪韫,等.CD43在弥漫大B细胞淋巴瘤中的表达及临床意义[J].临床血液学杂志,2018,31(5):343-347.
[15]	Lyman GH,Lyman CH,Agboola O.Risk models for predicting chemotherapy-induced neutropenia[J].Oncologist,2005,10:427-437.
[16]	Pettengell R,Schwenkglenks M.Incidence of neutropenia,chemotherapy delivery,and use of colony-stimulating factor in patients with non-Hodgkin lymphoma of different age groups[J].Leuk Lymphoma,2011,52:1133-1136.
[17]	Schwartzberg LS,Saleh M,Whittaker S,et al.Severe neutropenia and relative dose intensity among patients<65 and>/=65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy[J].Support Care Cancer,2014,22:1833-1841.
[18]	Lee KW,Kim DY,Yun T,et al.Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients:comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage[J].Cancer,2003,98:2651-2656.
[19]	徐兵河,田富国,喻璟瑞,等.聚乙二醇化重组人粒细胞刺激因子预防化疗后中性粒细胞减少的多中心随机对照Ⅲ期临床研究[J].中华肿瘤杂志,2016,38(1):23-27.
[20]	Zhou C,Huang Y,Wang D,et al.A randomized multicenter phase III study of single administration of mecapegfilgrastim (HHPG-19K),a pegfilgrastim biosimilar,for prophylaxis of chemotherapy-induced neutropenia in patients with advanced non-small-cell lung cancer (NSCLC)[J].Clin Lung Cancer,2016,17:119-127.
[21]	George S,Yunus F,Case D,et al.Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma[J].Leuk Lymphoma,2003,44:1691-1696.
[22]	Pettengell R,Schwenkglenks M,Bacon P,et al.Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma:results from an integrated analysis[J].Hematol Oncol,2011,29:177-184.
[23]	杨晟,何小慧,刘鹏,等.聚乙二醇化重组人粒细胞集落刺激因子预防化疗后中性粒细胞减少的有效性分析[J].中国肿瘤临床,2015,42(12):626-631.
[24]	Pawloski PA,Larsen M,Thoresen A,et al.Pegfilgrastim use and bone pain:a cohort study of community-based cancer patients[J].J Oncol Pharm Pract,2016,22:423-429.